Demographics and baseline characteristics. Values are mean (SD) unless otherwise specified.
| Characteristic | Placebo, n = 63 | Brodalumab | ||
|---|---|---|---|---|
| 70 mg, n = 63 | 140 mg, n = 63 | 210 mg, n = 63 | ||
| Male, n (%) | 12 (19) | 13 (21) | 14 (22) | 13 (21) |
| Race, n (%) | ||||
| White | 48 (76) | 53 (84) | 50 (79) | 56 (89) |
| African American | 1 (2) | 1 (2) | 1 (2) | 0 (0) |
| Hispanic or Latino | 14 (22) | 8 (13) | 12 (19) | 6 (10) |
| Asian | 0 (0) | 1 (2) | 0 (0) | 1 (2) |
| Age, yrs | 51 (12) | 53 (11) | 55 (10) | 52 (10) |
| Weight, kg | 73 (15) | 74 (15) | 77 (17) | 74 (17) |
| Height, cm | 164 (8) | 164 (8) | 163 (10) | 164 (9) |
| BMI, kg/m2 | 27 (5) | 27 (5) | 29 (6) | 28 (6) |
| RF, n (%) | ||||
| No | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| Yes | 63 (100) | 62 (98) | 63 (100) | 62 (98) |
| Unknown | 0 (0) | 1 (2) | 0 (0) | 1 (2) |
| Anti-CCP, n (%) | ||||
| Negative | 8 (13) | 6 (7) | 8 (13) | 8 (13) |
| Positive | 55 (87) | 58 (89) | 55 (87) | 55 (87) |
| Unknown | 0 (0) | 1 (2) | 0 (0) | 0 (0) |
| MTX weekly dose, mg | 17 (3) | 16 (3) | 17 (6) | 17 (4) |
| Corticosteroid use, n (%) | 34 (54) | 42 (67) | 35 (56) | 31 (49) |
| Duration of RA at baseline, yrs | 8.1 (7.9) | 7.2 (6.8) | 7.6 (7.3) | 7.6 (6.9) |
| DAS28 | 6.5 (0.8) | 6.3 (0.8) | 6.5 (0.8) | 6.4 (0.7) |
| HAQ-DI | 1.4 (0.6) | 1.5 (0.6) | 1.4 (0.6) | 1.5 (0.6) |
| Swollen joint count | 14 (7) | 14 (6) | 14 (6) | 13 (5) |
| Tender joint count | 27 (15) | 25 (14) | 25 (14) | 23 (11) |
| Subject global assessment of disease activity | 5.9 (1.9) | 5.8 (1.8) | 6.0 (2.0) | 6.1 (1.9) |
| Physician global assessment of disease activity | 6.3 (1.5) | 6.4 (1.4) | 6.1 (1.3) | 6.3 (1.2) |
| Subject global assessment of pain | 54 (21) | 53 (22) | 50 (25) | 52 (22) |
| ESR, mm/h | 48 (20) | 45 (20) | 44 (21) | 45 (20) |
| CRP, mg/l | 13 (12) | 14 (17) | 18 (23) | 12 (11) |
BMI: body mass index; RF: rheumatoid factor; anti-CCP: anticyclic citrullinated peptide antibodies; MTX: methotrexate; RA: rheumatoid arthritis; DAS28: Disease Activity Score at 28 joints; HAQ-DI: Health Assessment Questionnaire–Disability Index; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein.